Shares fell 2.5% as investors appeared cautious despite steady growth, likely signaling concerns over a lack of clear acceleration or upside in guidance and margins.
- New business profit grew 8% in H1 2026, accompanied by 17% growth in earnings per share and a 15% rise in free surplus generation.
- New business margin expanded 2 percentage points to 40%, with a shift towards health and protection products supporting margin improvement potential.
- Underlying variances returned to positive territory, reflecting improved claims management and cost control, though no clear guidance upgrade was communicated.
- Capital position remains robust with a free surplus ratio near the top of the target range and ongoing share buybacks totaling $1.5 billion planned through 2026.
- Management reaffirmed delivery of double-digit growth guidance for 2026 and medium-term 2027 financial objectives, but provided limited incremental detail to excite investors.
Community Discussion